These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia. Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593 [TBL] [Abstract][Full Text] [Related]
28. Peripheral Markers of Vascular Endothelial Dysfunction Show Independent but Additive Relationships with Brain-Based Biomarkers in Association with Functional Impairment in Alzheimer's Disease. Drake JD; Chambers AB; Ott BR; Daiello LA; J Alzheimers Dis; 2021; 80(4):1553-1565. PubMed ID: 33720880 [TBL] [Abstract][Full Text] [Related]
29. Elevated Inflammatory Markers and Arterial Stiffening Exacerbate Tau but Not Amyloid Pathology in Older Adults with Mild Cognitive Impairment. Clark AL; Weigand AJ; Thomas KR; Solders SK; Delano-Wood L; Bondi MW; Bernier RA; Sundermann EE; Banks SJ; Bangen KJ; J Alzheimers Dis; 2021; 80(4):1451-1463. PubMed ID: 33682714 [TBL] [Abstract][Full Text] [Related]
30. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease. Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875 [TBL] [Abstract][Full Text] [Related]
31. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Ritchie C; Smailagic N; Noel-Storr AH; Takwoingi Y; Flicker L; Mason SE; McShane R Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD008782. PubMed ID: 24913723 [TBL] [Abstract][Full Text] [Related]
32. Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment. Baldeiras I; Santana I; Leitão MJ; Gens H; Pascoal R; Tábuas-Pereira M; Beato-Coelho J; Duro D; Almeida MR; Oliveira CR Alzheimers Res Ther; 2018 Mar; 10(1):33. PubMed ID: 29558986 [TBL] [Abstract][Full Text] [Related]
33. Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease. Sala I; Illán-Gala I; Alcolea D; Sánchez-Saudinós MB; Salgado SA; Morenas-Rodríguez E; Subirana A; Videla L; Clarimón J; Carmona-Iragui M; Ribosa-Nogué R; Blesa R; Fortea J; Lleó A J Alzheimers Dis; 2017; 58(3):909-918. PubMed ID: 28527215 [TBL] [Abstract][Full Text] [Related]
34. Racial Disparity in Cerebrospinal Fluid Amyloid and Tau Biomarkers and Associated Cutoffs for Mild Cognitive Impairment. Garrett SL; McDaniel D; Obideen M; Trammell AR; Shaw LM; Goldstein FC; Hajjar I JAMA Netw Open; 2019 Dec; 2(12):e1917363. PubMed ID: 31834392 [TBL] [Abstract][Full Text] [Related]
35. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid. Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990 [TBL] [Abstract][Full Text] [Related]
36. Gait Disturbances are Associated with Increased Cognitive Impairment and Cerebrospinal Fluid Tau Levels in a Memory Clinic Cohort. Muurling M; Rhodius-Meester HFM; Pärkkä J; van Gils M; Frederiksen KS; Bruun M; Hasselbalch SG; Soininen H; Herukka SK; Hallikainen M; Teunissen CE; Visser PJ; Scheltens P; van der Flier WM; Mattila J; Lötjönen J; de Boer C J Alzheimers Dis; 2020; 76(3):1061-1070. PubMed ID: 32597806 [TBL] [Abstract][Full Text] [Related]
37. The recency ratio is related to CSF amyloid beta 1-42 levels in MCI-AD. Bruno D; Gleason CE; Koscik RL; Pomara N; Zetterberg H; Blennow K; Johnson SC Int J Geriatr Psychiatry; 2019 Mar; 34(3):415-419. PubMed ID: 30430632 [TBL] [Abstract][Full Text] [Related]
38. Chronic depressive symptomatology and CSF amyloid beta and tau levels in mild cognitive impairment. Gonzales MM; Insel PS; Nelson C; Tosun D; Schöll M; Mattsson N; Sacuiu S; Bickford D; Weiner MW; Mackin RS; Int J Geriatr Psychiatry; 2018 Oct; 33(10):1305-1311. PubMed ID: 29953668 [TBL] [Abstract][Full Text] [Related]
39. Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. Toledo JB; Weiner MW; Wolk DA; Da X; Chen K; Arnold SE; Jagust W; Jack C; Reiman EM; Davatzikos C; Shaw LM; Trojanowski JQ; Acta Neuropathol Commun; 2014 Mar; 2():26. PubMed ID: 24602322 [TBL] [Abstract][Full Text] [Related]
40. Can Subjective Memory Complaints Identify Aβ Positive and Aβ Negative Amnestic Mild Cognitive Impairment Patients? Mendes T; Cardoso S; Guerreiro M; Maroco J; Silva D; Alves L; Schmand B; Gerardo B; Lima M; Santana I; de Mendonça A J Alzheimers Dis; 2019; 70(4):1103-1111. PubMed ID: 31306132 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]